Cartesian Therapeutics, Inc. Operating Lease Liability
Cartesian Therapeutics, Inc. (RNAC) had Operating Lease Liability of $11.00 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-08-06
- 2026-06-30: Operating Lease, Liability $11.00M.
- 2026-03-31: Operating Lease, Liability $11.86M.
- 2025-12-31: Operating Lease, Liability $12.68M.
- 2025-09-30: Operating Lease, Liability $12.60M.
| Period end | Operating Lease, Liability |
|---|---|
| 2026-06-30 | $11.00M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $11.86M 10-Q · filed 2026-04-30 |
| 2025-12-31 | $12.68M 10-K · filed 2026-03-09 |
| 2025-09-30 | $12.60M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $13.35M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $14.07M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $13.98M 10-K · filed 2025-03-13 |
| 2024-09-30 | $14.65M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $14.87M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $10.46M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $10.96M 10-K · filed 2024-03-07 |
| 2023-09-30 | $10.48M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $10.89M 10-Q · filed 2023-08-17 |
| 2023-03-31 | $11.29M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $11.66M 10-K · filed 2023-03-02 |
| 2022-09-30 | $12.06M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $9.14M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $9.40M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $9.65M 10-K · filed 2022-03-10 |
| 2021-09-30 | $9.89M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $10.12M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $10.35M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $10.55M 10-Q · filed 2021-08-12 |
| 2020-09-30 | $10.76M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $11.77M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $11.87M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $372.00K 10-K · filed 2021-03-12 |
| 2019-09-30 | $734.00K 10-Q · filed 2019-11-08 |
| 2019-06-30 | $1.08M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $1.43M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |